The high-throughput screening system for inhibitor mycobacterium tuberculosis compounds based on atp hydrolysis activity of recombinant protein CLPC1

Abstract

The global Tuberculosis (TB) rate continues to increase by 1% per year with the widespread of dmg-resistant TB. Therefore, the development and research to find new anti-TB drugs are becoming an extremely urgent mission. To be able to screen lead anti-tuberculosis drugs, currently, researchers have to carry out directly on the cells of Mycobacterium tuberculosis and to be performed in bio-security facilities level 3 or 4, to prevent infection from pathogens. However, our results demonstrated that the screening of anti-TB drug candidates can be implemented in bio-security facilities level 1 laboratory with the Escherichia coli cell extraction and recombinant ClpC1 protein - an integral part of the Mycobacterium tuberculosis genome.